Form4insider filings, from the source

SEC Form 4 · accession 0000899243-18-013013

Evelo Biosciences, Inc. · EVLO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Noubar Afeyan
Director · 10% Owner
Period of report
May 11, 2018
Accepted (ET)
May 15, 2018 · 8:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001694665

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2,F3,F4,F5May 11, 2018C14,622,143$0.00A17,952,153ISee footnotes
Common StockF6,F1,F2,F3,F4,F5May 11, 2018P281,250$16.00A18,233,403ISee footnotes

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A Preferred StockF1,F2,F3,F4,F5,F7—May 11, 2018C12,536,945D——Common Stock3,073,5330I
Series A-1 Preferred StockF1,F2,F3,F4,F5,F7—May 11, 2018C10,102,055D——Common Stock2,476,6000I
Series A-2 Preferred StockF1,F2,F3,F4,F5,F7—May 11, 2018C5,416,667D——Common Stock1,327,9390I
Series A-3 Preferred StockF1,F2,F3,F4,F5,F7—May 11, 2018C8,333,000D——Common Stock2,042,9020I
Series B Preferred StockF1,F2,F3,F4,F5,F7—May 11, 2018C18,611,110D——Common Stock4,562,6640I
Series C Preferred StockF1,F2,F3,F4,F5,F7—May 11, 2018C4,643,963D——Common Stock1,138,5050I

Explanation of responses

Remarks

Due to the limitations of the electronic filing system each of Flagship Ventures Fund IV General Partner LLC, Flagship VentureLabs IV LLC, Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. are filing a separate Form 4.